Fundraising FoxSofinnova Ventures — 2023 Investments
5 investments dated 2023 · listed companies and verified rows first · show all
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)Steven Paul David Bredt(Founder)
Co-investorsARCH Venture PartnersCapital GroupJohnson & Johnson Innovation – JJDCThird Rock Ventures
Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.
AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL
Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in
BoardEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)
Board seatJonathan Leff· per SEC Form D · $30M raise · filed Jun 2023
Co-investorsHackensack Meridian Health Bear's DenMaryland TEDCOTEDCOAMR Action FundDeerfield Management Company
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardRobert Jackson(Director)
Board seatJonathan Leff· per SEC Form D · $2.8M raise · filed Aug 2023
Co-investorsBiotech Investments S.R.Oi&i Biotech FundOUP (Osage University Partners)Deerfield Management Company
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
BiotechHealthtechSan Diego, US
Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)
BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)
Board seatJonathan Leff· per SEC Form D · $189.2M raise · filed Oct 2023
Co-investorsF-Prime CapitalNorwest Venture PartnersRiverVest Venture Partners
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)inJoseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatDavid Kabakoff· per SEC Form D · $35.7M raise · filed Jul 2023
Co-investors5AM VenturesArboretum VenturesF-Prime CapitalTelegraph Hill PartnersHealthQuest Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.